VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MNPR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MNPRMonopar Therapeutics Inc.
$71.97$482M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMNPRFinancials

Monopar Therapeutics Inc. (MNPR) Income Statement

11Y historyFree accessUpdated daily

Revenue remains nil across the reported periods while operating losses have widened, reaching -$7.5M in 2026Q3 against R&D expense of $4.4M and SG&A of $3.0M, indicating no commercial offset to clinical spending.

Income StatementBalance SheetCash FlowRatios

MNPR Income Statement

Annual statement

MNPR Income Statement

Monopar Therapeutics Inc. (MNPR) annual income statement — 11-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15
Sales/Revenue000000000000
Revenue Growth %------------
Cost of Goods Sold000000000000
COGS % of Revenue------------
Gross Profit000000000000
Gross Margin %------------
Gross Profit Growth %------------
Operating Expenses25.49M16.7M16.16M8.83M10.54M9.13M6.51M4.32M3.4M16.6M1.19M688.56K
OpEx % of Revenue------------
Selling, General & Admin1.75B6.8B3.16M3.23M2.95M2.63M2.44M2.36M1.63M1.17M912.47K587.08K
SG&A % of Revenue------------
Research & Development16.63M9.9B13.01M5.6M7.59M6.49M4.07M1.97M1.77M935.32K280.36K101.49K
R&D % of Revenue------------
Other Operating Expenses-1000K-16.69B000000014.5M00
Operating Income-25.49M-16.7M-16.16M-8.83M-10.54M-9.13M-6.51M-4.32M-3.4M-16.6M-1.19M-689K
Operating Margin %------------
Operating Income Growth %--3.36%-83.01%16.19%-15.44%-40.23%-50.54%-27.06%79.5%-1291.9%-73.12%-
EBITDA-20.6M-13.72M-15.59M-8.4M-10.52M-9.1M0-4.22M-71.85K-14.5M0-438
EBITDA Margin %------------
EBITDA Growth %-2.52%11.99%-85.5%20.1%-15.52%-100%-5779.89%99.5%-100%-
D&A (Non-Cash Add-back)0000006.51M03.33M2.1M1.19M688.56K
EBIT-20.6M-13.72M-15.59M-8.4M-10.52M-9.1M-6.51M-4.22M-3.33M-16.55M-1.18M-687K
Net Interest Income4.86M2.99M404.02K429.04K21.24K24.02K81.9K98.89K0000
Interest Income4.86M2.99M404.02K429.04K21.24K24.02K81.9K98.89K103.22K48.26K7.23K1.25K
Interest Expense00000000103.22K48.26K7.23K0
Other Income/Expense4.89M2.99M575.3K429.04K21.24K24.02K204.3K98.89K31.15K48.26K7.23K1.25K
Pretax Income-20.6M-13.72M-15.59M-8.4M-10.52M-9.1M-6.3M-4.22M-3.3M-16.55M-1.18M-687K
Pretax Margin %------------
Income Tax00000000-71.61K08000
Effective Tax Rate %0%0%0%0%0%0%0%0%2.17%0%-0.07%0%
Net Income-20.6M-13.72M-15.59M-8.4M-10.52M-9.1M-6.3M-4.22M-3.23M-16.55M-1.19M-687K
Net Margin %------------
Net Income Growth %-5.98%11.99%-85.5%20.1%-15.52%-44.39%-49.23%-30.88%80.5%-1296.34%-72.58%-
Net Income (Continuing)-20.6M-13.72M-15.59M-8.4M-10.52M-9.1M-6.3M-4.22M-3.23M-16.55M-1.19M-687K
Discontinued Operations000000000000
Minority Interest000000000000
EPS (Diluted)-2.41-1.85-1.36-0.58-0.83-0.73-0.58-0.40-0.31-1.59-0.12-0.08
EPS Growth %-19.44%-36.03%-134.48%30.12%-13.7%-25.86%-45%-29.03%80.5%-1225%-42.52%-
EPS (Basic)--1.85-1.36-0.58-0.83-0.73-0.58-0.40-0.31-1.59-0.12-0.08
Diluted Shares Outstanding8.56M7.41M11.48M14.51M12.72M12.47M10.96M10.59M10.42M10.42M9.86M8.16M
Basic Shares Outstanding8.56M7.41M11.44M14.51M12.72M12.47M10.96M10.59M10.42M10.42M9.85M8.16M
Dividend Payout Ratio------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Ongoing clinical cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Losses Widening Without Revenue Offset

Based on reported quarterly income statements, MNPR has recorded zero revenue across all ten periods, with operating losses swinging from -$1.6M in 2024Q3 to -$11.1M in 2024Q4 and reaching -$7.5M in 2026Q3.

The absence of any top-line revenue means the trajectory is defined entirely by expense growth rather than commercial scaling. The pattern of lumpy R&D spend, including a $9.9M quarter in 2024Q4, suggests clinical program timing rather than a steady operating cadence. Investors should treat the trend as a function of trial activity and monitor whether losses moderate as programs mature.

R&D Drives the Entire Expense Base

As reported in the income statement, research and development expense accounts for nearly all operating spend, running between $984.3K and $9.9M per quarter, while SG&A stays in a narrower $590.6K to $3.0M band.

R&D dominance is consistent with a company advancing Validive and Camsirubicin through clinical stages, where enrollment and site costs dictate quarterly variance. SG&A has stepped up alongside the 2026 quarters, which may reflect pre-commercial or corporate infrastructure build-out, though the data alone does not confirm the purpose. Expense discipline cannot be fully judged without knowing how much of R&D is externally contracted.

Net Losses Track Operating Losses Closely

Based on reported figures, net loss has tracked operating loss closely across the period, with 2026Q3 showing -$6.2M net against -$7.5M operating, and EPS deteriorating to -$0.72 in the most recent quarter.

The small gap between operating and net loss suggests limited non-operating income or tax effects are distorting reported earnings. Stock-based compensation is modest relative to losses, so dilution-related quality concerns appear secondary to the underlying cash burn. Share count changes should be checked against EPS to separate loss growth from equity issuance effects.

2024Q4 Spike Marks Program Escalation

According to the reported quarterly figures, the 2024Q4 period stands out with R&D jumping to $9.9M from roughly $1.1M the prior quarter, lifting the operating loss to -$11.1M and EPS to -$0.95.

This step-change in R&D appears to coincide with clinical program escalation, though the income statement alone cannot identify the specific trials responsible. The quarter represents the sharpest single-period loss in the dataset and set a higher expense base that subsequent quarters have only partially unwound. Its lasting effect is a structurally higher burn level that investors should weigh against remaining cash runway.

Expense Growth Without Commercial Traction

Based on the reported income statements, the bear case rests on sustained operating losses of roughly -$5M to -$7M per quarter in 2026 with no revenue to offset them, implying continued dependence on external capital.

A skeptic would argue that absent revenue, each additional clinical quarter compounds losses without proof of commercial viability, and that the rising SG&A trend in 2026 adds overhead before any product is approved. Negative return on equity reinforces that capital has not yet generated returns. This analysis is inferential, and the conclusion depends on clinical outcomes not captured in the financial data provided.

MNPR — Frequently Asked Questions

Quick answers to the most common questions about buying MNPR stock.

What was Monopar Therapeutics Inc.'s (MNPR) revenue in 2025?

For fiscal year 2025, Monopar Therapeutics Inc. (MNPR) reported total revenue of $0.0M.

Is Monopar Therapeutics Inc. (MNPR) profitable?

Monopar Therapeutics Inc. (MNPR) reported a net loss of $13.7M for the fiscal year ending 2025.